We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Wyeth Extends Agreement with Affymetrix to 15 Years

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Wyeth Extends Agreement with Affymetrix to 15 Years"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Affymetrix Inc. has announced that Wyeth has signed another agreement with Affymetrix to use GeneChip® microarray technology for three more years, further extending the relationship that began in 1994.

Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process.

Wyeth was one of the first pharmaceutical companies to apply genomics in clinical research. The company will continue to use Affymetrix microarray technology to identify new drug targets and gain a better understanding of the genetic markers that potentially correlate with a patient’s response to therapy.

The latest GeneChip technology enables them to more accurately classify disease, predict clinical progression and determine likelihoods of treatment success in ways never before possible.

“Wyeth has been a pioneer in demonstrating the power of Affymetrix microarray technology in the entire drug discovery and development process,” said Chip Leveille, vice president, Pharmaceutical Business Unit at Affymetrix.

“We anticipate that a better understanding of human genetic variations and the ability to look at the entire genome in greater detail will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster.”